Theradaptive closed a $26 million Series A funding round to advance development of its targeted regenerative therapeutics.
The funds will enable the company to continue its work to meet regulatory requirements and scale up Good Manufacturing Practices in preparation for first-in-human clinical trials later this year. Investment will also support the expansion of the Theradaptive platform beyond orthopedics to additional indications such as oncology and dental. The round brings Theradaptive’s total funding to over $50 million.
Theradaptive’s proprietary protein-engineering platform produces targeted therapeutics that can be used to coat implants, devices and injectable carriers to achieve hyper-local delivery over long time periods exceeding weeks to months.
With this technology, FDA has granted an unprecedented three breakthrough medical device designations to Theradaptive for its various spinal indications.
Source: Theradaptive
Theradaptive closed a $26 million Series A funding round to advance development of its targeted regenerative therapeutics.
The funds will enable the company to continue its work to meet regulatory requirements and scale up Good Manufacturing Practices in preparation for first-in-human clinical trials later this year. Investment will also...
Theradaptive closed a $26 million Series A funding round to advance development of its targeted regenerative therapeutics.
The funds will enable the company to continue its work to meet regulatory requirements and scale up Good Manufacturing Practices in preparation for first-in-human clinical trials later this year. Investment will also support the expansion of the Theradaptive platform beyond orthopedics to additional indications such as oncology and dental. The round brings Theradaptive’s total funding to over $50 million.
Theradaptive’s proprietary protein-engineering platform produces targeted therapeutics that can be used to coat implants, devices and injectable carriers to achieve hyper-local delivery over long time periods exceeding weeks to months.
With this technology, FDA has granted an unprecedented three breakthrough medical device designations to Theradaptive for its various spinal indications.
Source: Theradaptive
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.